Table 1.
Major Trials of Intravenous and Intra-Arterial Treatment for Acute Ischemic Stroke
Major Stroke Treatment Trials
|
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NINDS rt-PA18 |
NINDS rt-PA Control18 |
SITS- MOST15 |
PROACT II rtPA19 |
PROACT-II Control19 |
MELT rtPA20 |
MELT Control20 |
IMS-121 | IMS-222 | CLOTBUST23 | EKOS 124 |
MERCI 225 |
MULTI- MERCI26 |
Penumbra Pivotal27 |
|
Patients, n | 312 | 312 | 6483 | 121 | 59 | 57 | 57 | 80 | 81 | 63 | 14 | 141 | 164 | 125 |
Age, y | 68 | 66 | 68 | 64 | 64 | 67 | 67 | 64 | 67 | 67 | 64 | 67 | 68 | 64 |
Baseline NIHSS | 18 | 18 | 12 | 17 | 17 | 14 | 14 | 18 | 19 | 16 | 18 | 20 | 19 | 18 |
Revascularization, % | 66 | 18 | 73 | 56 | 60 | 38 | 57 | 48 | 68 | 82 | ||||
Symptomatic ICH, % | 1 | 7 | 1.7 | 10.9 | 2 | 9 | 2 | 6 | 10 | 4.8 | 14 | 7.8 | 9.8 | 11.2 |
Asymptomatic ICH, % | 0.5 | 24 | 43 | 27.7 | 30.5 | 16.8 | ||||||||
90-d mortality, % | 24 | 21 | 11 | 25 | 27 | 5.3 | 3.5 | 16 | 16 | 15 | 36 | 43.5 | 34 | 32.8 |
90-d mRS ≤2 | 28 | 30 | 54 | 40 | 25 | 49.1 | 38.6 | 43 | 46 | 42 | 43 | 27.7 | 36 | 25 |
NINDS rt-PA indicates National Institute of Neurological Disorders Tissue Plasminogen Activator for Acute Ischemic Stroke Trial; SITS-MOST, Safe Implementation of Thrombolysis in Stroke-Monitoring Study; PROACT II, Prolyse in Acute Cerebral Thromboembolism trial; rtPA, recombinant tissue-type plasminogen activator; MELT, Middle Cerebral Artery Embolism Local Fibrinolytic Intervention Trial; IMS, Interventional Management of Stroke; CLOTBUST, randomized trial of ultrasound-enhanced thrombolysis for acute ischemic stroke; EKOS, EKOS MicroLysUS infusion catheter study; MERCI, Mechanical Embolus Removal in Cerebral Ischemia; NIHSS, National Institutes of Health Stroke Scale; ICH, intracranial hemorrhage; and mRS, modified Rankin Scale.